---
layout: post
title: 'ESMO 2025' 
date: 2025-11-02
---

## 关注

- LBA72 NorthStar 
- LBA77 FLAURA2
- LBA65 MDT-BRIDGE
- LBA69 SKYSCRAPER-03
- LBA54 - SARS-CoV-2 mRNA vaccines 
- TALENTop 


## ESMO 2025 

- [Proffered paper session: NSCLC metastatic (Fri, 17.10.2025)](https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal/show/session/103)
  - LBA72 NorthStar: A phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR-mutant non-small cell lung cancer (NSCLC) - NCT04479306
    - The addition of local consolidative therapy to osimertinib significantly extends progression-free survival in patients with EGFR-mutant metastatic NSCLC, even in the setting of polymetastatic disease. These results support the integration of LCT into the treatment paradigm for appropriately selected patients receiving EGFR-targeted therapy and may inform future standards of care.
    - 远离丁为民、张力这种消极的医生，ESMO 2025 公布结果即使是 polymetastatic diease 的人做姑息治疗，也有近8个月的PFS提升 (已经接近某些二线用药的 PFS)。谁说姑息治疗没有意义？
  - LBA75 Sevabertinib
  - LBA74 Zongertinib
  - LBA77 FLAURA2: Exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for EGFR-mutated (EGFRm) advanced NSCLC
    - A survival benefit favouring osi + CTx vs osi mono was consistently observed across each prognostic subgroup evaluated, reinforcing osi + CTx as a 1L standard of care in this setting. Table: LBA77
    - 奥希替尼+化疗 mOS
      - L858R vs Ex19del : 32.4 vs 43.0 (L858R少11个月)
      - Tissue TP53 altered vs wild type : 43.1 vs NR (TP53变异预后不佳，如果治疗中转阴?)
      - Plasma EGFRm Det vs Undet: 	32.5 vs NR (血浆中的 EGFR突变，即 MRD. 这种重要的东西周清竟然不推荐?医生替病人想经济上的事情管太多了。如果治疗过程中 ctDNA 的 EGFR突变消失，这些病人的生存期更长，而且实验的随访时间已经够长了，还是 NR 证明这群人已经有5年临床治愈的可能了)。我要是知道4周内MRDctDNA效果好就直接采取更激进的治疗方式了。
      - Baseline CNS mets Yes vs No: 29.7 vs 43.9 (脑转移少1年多的生存期。第一件事情，不要因为保险报销问题，而不选择第三方检测机构，病情比金钱重要。如果刚开始舍得花2-3万做 MRD的检测，坚持自己想法，不听周清的，不会拖到脑转移也没有采取行动。命比钱重要，觉得对的就不惜代价去做)。另外 韩宝惠、赵洪云、颜教授 之流也是太保守，**杨农** 这种才是真高手。
  - LBA73 ALK
- [Proffered paper session: Non-metastatic NSCLC](https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal/show/session/107)
  - 2757O Tarlatamab: DLL3 小细胞癌神药
  - 2761O Chemo-immunotherapy followed by durvalumab and ceralasertib in treatment naïve patients with extensive-stage small cell lung cancer
    - 小细胞癌治疗方案
  - LBA65 Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: Interim analysis (IA) of the phase II MDT-BRIDGE study
    - 类似 中肿刘慧的结果。surgery (Sx) and adjuvant Durvalumab or Chemoradiotherapy(CRT) and consolidation Durvalumab in patients. 手术后度伐利尤单抗新辅助治疗 ，或者在 CRT 同步放化疗后度伐利尤单抗巩固治疗
  - LBA69 SKYSCRAPER-03: Phase III, open-label, randomised study of atezolizumab (atezo) + tiragolumab (tira) vs durvalumab (durva) in locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) after platinum-based concurrent chemoradiation (cCRT)
    - 类似上一个，cCRT (同步放化疗) 后 阿替利珠单抗+提雷戈单抗 对比 度伐利尤单抗 的术后新辅助治疗。提雷戈单抗是TIGIT单抗。但是 阿替利珠单抗+提雷戈单抗 是阴性结果。
- 